Spero Therapeutics, Inc. – NASDAQ:SPRO

Add to watchlist

$1.84

+0.81

+78.64%

Market closed

Open in 3 days

-27.46%

month

-27.46%

quarter

-26.43%

year

Market Cap	52.55M
Enterprise value	N/A

P/E	-1.27
EV/Sales	-24.97
EV/EBITDA	1.46
Price/Sales	0.01
Price/Book	N/A
PEG ratio	-0.02
EPS	0.43

Revenue	102.29M
EBITDA	16.08M
Income	23.40M
Revenue Q/Q	468.10%
Revenue Y/Y	108.67%

Profit margin	-1786.12%
Oper. margin	-1662.46%
Gross margin	21.86%
EBIT margin	-1662.46%
EBITDA margin	15.73%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Spero Therapeutics, Inc. (NASDAQ:SPRO): Profit margin
Jun 2023	788K	-11.91M	-1511.93%
Sep 2023	25.47M	-3.20M	-12.58%
Dec 2023	71.82M	51.19M	71.27%
Mar 2024	4.20M	-12.66M	-301.36%

Spero Therapeutics Financials Estimate

Q Y

Spero Therapeutics, Inc. (NASDAQ:SPRO): Analyst Estimates
Mar 2024	4.20M	-12.66M	-301.36%
Sep 2025	13M	-13.01M	-100.09%
Oct 2025	10.5M	-20.87M	-198.8%
Dec 2025	25M	-13.91M	-55.66%

Analysts Price target
Financials & Ratios estimates

Spero Therapeutics, Inc. (NASDAQ:SPRO): Debt to assets
Jun 2023	98885000	44.10M	44.6%
Sep 2023	107101000	53.39M	49.86%
Dec 2023	182390000	75.49M	41.39%
Mar 2024	167703000	71.45M	42.61%

Spero Therapeutics, Inc. (NASDAQ:SPRO): Cash Flow
Jun 2023	-18.56M	0
Sep 2023	15.91M	220K
Dec 2023	-17.49M	1K
Mar 2024	5.93M	0

Spero Therapeutics alternative data

Spero Therapeutics, Inc. (NASDAQ:SPRO): Employee count
Aug 2023	35
Sep 2023	35
Oct 2023	35
Nov 2023	35
Dec 2023	35
Jan 2024	35
Feb 2024	35
Mar 2024	46
Apr 2024	46
May 2024	46
Jun 2024	46
Jul 2024	46

Spero Therapeutics
Hedge Funds Holdings Q1 2023

13.56% -26.07%

of SPRO is owned by hedge funds

27 -28

hedge funds hold SPRO stock

5.09M -9.12M

shares is hold by hedge funds

SPRO hedge funds holdings changes

Spero Therapeutics
Insider Trading

Spero Therapeutics, Inc. (NASDAQ:SPRO): Insider trades (number of shares)
Period	Buy	Sel
Aug 2023	0	18765
Sep 2023	0	39496
Feb 2024	0	229741

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	5 Feb 2024	SHUKLA SATH director, officer: CEO and President director, officer: CEO and Pres..	Common Stock	45,093	$1.45	$65,385
Sale	2 Feb 2024	HAMED KAMAL officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	28,075	$1.37	$38,463
Sale	2 Feb 2024	KEUTZER TIMOTHY officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	30,971	$1.36	$42,121
Sale	2 Feb 2024	MAHADEVIA ANKIT director	Common Stock	63,795	$1.37	$87,399
Sale	2 Feb 2024	JOSEPH TAMARA L officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	30,906	$1.37	$42,341
Sale	2 Feb 2024	SHUKLA SATH director, officer: CEO and President director, officer: CEO and Pres..	Common Stock	30,901	$1.37	$42,334
Sale	13 Sep 2023	HAMED KAMAL officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	39,496	$1.27	$50,160
Sale	29 Aug 2023	SHUKLA SATH director, officer: CEO and President director, officer: CEO and Pres..	Common Stock	4,163	$1.3	$5,412
Sale	28 Aug 2023	KEUTZER TIMOTHY officer: Chief Development Officer officer: Chief Development Offi..	Common Stock	1,854	$1.26	$2,336
Sale	28 Aug 2023	JOSEPH TAMARA L officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	1,854	$1.26	$2,336

SPRO insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application HIGH DOSAGE TEBIPENEM PIVOXIL TABLET FORMULATION Filling date: 12 Nov 2021 Issue date: 12 May 2022	12 Nov 2021	12 May 2022
Application	Application COMPOUNDS Filling date: 25 Jun 2019 Issue date: 12 Aug 2021	25 Jun 2019	12 Aug 2021
Application	Application POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS Filling date: 25 Jan 2021 Issue date: 22 Jul 2021	25 Jan 2021	22 Jul 2021
Application	Application TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USE Filling date: 29 Dec 2020 Issue date: 29 Apr 2021	29 Dec 2020	29 Apr 2021
Application	Application TEBIPENEM PIVOXIL CRYSTALLINE FORMS, COMPOSITIONS INCLUDING THE SAME, METHODS OF MANUFACTURE, AND METHODS OF USE Filling date: 6 Feb 2018 Issue date: 20 Feb 2020	6 Feb 2018	20 Feb 2020
Application	Application NOVEL TEBIPENEM PIVOXIL IMMEDIATE AND MODIFIED RELEASE ORAL DOSAGE FORMS Filling date: 15 Dec 2017 Issue date: 16 Jan 2020	15 Dec 2017	16 Jan 2020

Spero Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q4 2023 13 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 13 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 10 Aug 2023	Q2 2023 Earnings Call Transcript
Q1 2023 11 May 2023	Q1 2023 Earnings Call Transcript

SPRO earnings call transcripts

Spero Therapeutics
Executives

Insider	Age	Compensation
Dr. Ankit Mahadevia M.D., MBA (1981) Co-Founder, Chief Executive Officer, Pres & Director	44	$966,830
Dr. David A. Melnick M.D. (1952) Chief Medical Officer	73	$647,310
Ms. Cristina Larkin (1970) Chief Operating Officer	55	$639,360

Spero Therapeutics
Latest News

Monday, 16 December 2024
19:36	Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner	zacks.com
Friday, 15 November 2024
05:45	New Strong Buy Stocks for November 15th	zacks.com
Thursday, 14 November 2024
18:36	Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates	zacks.com
16:05	Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update	globenewswire.com
Wednesday, 16 October 2024
16:05	Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024	globenewswire.com
Wednesday, 2 October 2024
16:30	Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy	globenewswire.com
Friday, 9 August 2024
10:47	Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript	seekingalpha.com
Monday, 5 August 2024
18:35	Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
16:01	Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update	globenewswire.com
Monday, 29 July 2024
16:05	Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024	globenewswire.com
Monday, 8 July 2024
15:07	3 Micro-Cap Moonshots for Fearless Investors	investorplace.com
Wednesday, 3 July 2024
13:05	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Monday, 3 June 2024
16:05	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Monday, 20 May 2024
01:06	HC Wainwright Brokers Boost Earnings Estimates for Spero Therapeutics, Inc. (NASDAQ:SPRO)	https://www.defenseworld.net
Thursday, 16 May 2024
16:05	Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference	globenewswire.com
Wednesday, 15 May 2024
16:05	Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update	globenewswire.com
Wednesday, 8 May 2024
08:00	Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024	globenewswire.com
Wednesday, 1 May 2024
16:07	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Tuesday, 23 April 2024
11:37	Spero Therapeutics Delivers On Game Plan To Create Shareholder Value	seekingalpha.com
Wednesday, 13 March 2024
18:10	Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates	Zacks Investment Research
Wednesday, 6 March 2024
08:05	Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024	GlobeNewsWire
Monday, 26 February 2024
08:05	Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference	GlobeNewsWire
Monday, 13 November 2023
19:05	Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript	Seeking Alpha
Monday, 6 November 2023
08:05	Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023	GlobeNewsWire
Wednesday, 18 October 2023
13:32	All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy	Zacks Investment Research
Wednesday, 20 September 2023
16:05	Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference	GlobeNewsWire
Wednesday, 6 September 2023
08:05	Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference	GlobeNewsWire
Tuesday, 29 August 2023
13:31	Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?	Zacks Investment Research
09:01	New Strong Buy Stocks for August 29th	Zacks Investment Research
Tuesday, 22 August 2023
18:47	Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround	Zacks Investment Research

Frequently Asked Questions (FAQ)

What's the price of Spero Therapeutics stock today?

One share of Spero Therapeutics stock can currently be purchased for approximately $1.84.
When is Spero Therapeutics's next earnings date?

Unfortunately, Spero Therapeutics's (SPRO) next earnings date is currently unknown.
Does Spero Therapeutics pay dividends?

No, Spero Therapeutics does not pay dividends.
How much money does Spero Therapeutics make?

Spero Therapeutics has a market capitalization of 52.55M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 99.13% to 96.74M US dollars.
What is Spero Therapeutics's stock symbol?

Spero Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SPRO".
What is Spero Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Spero Therapeutics?

Shares of Spero Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Spero Therapeutics's key executives?
Spero Therapeutics's management team includes the following people:
- Dr. Ankit Mahadevia M.D., MBA Co-Founder, Chief Executive Officer, Pres & Director(age: 44, pay: $966,830)
- Dr. David A. Melnick M.D. Chief Medical Officer(age: 73, pay: $647,310)
- Ms. Cristina Larkin Chief Operating Officer(age: 55, pay: $639,360)
Is Spero Therapeutics founder-led company?

Yes, Spero Therapeutics is a company led by its founder Dr. Ankit Mahadevia M.D., MBA.
How many employees does Spero Therapeutics have?

As Jul 2024, Spero Therapeutics employs 46 workers.
When Spero Therapeutics went public?

Spero Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 2 Nov 2017.
What is Spero Therapeutics's official website?

The official website for Spero Therapeutics is sperotherapeutics.com.
Where are Spero Therapeutics's headquarters?

Spero Therapeutics is headquartered at 675 Massachusetts Avenue, Cambridge, MA.
How can i contact Spero Therapeutics?

Spero Therapeutics's mailing address is 675 Massachusetts Avenue, Cambridge, MA and company can be reached via phone at 857 242 1600.

Spero Therapeutics, Inc.

sperotherapeutics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

857 242 1600

675 Massachusetts Avenue
Cambridge, MA 02139

CIK: 0001701108
ISIN: US84833T1034
CUSIP: 84833T103